Conversion to sirolimus in renal transplant recipients: A single-center experience

Artificial Organs

Volumn 34, Issue 8, 2010, Pages

  Yelken, Berna ^a   Caliskan, Yasar ^a   Ozkan, Oktay ^a   Gorgulu, Numan ^a   Yazici, Halil ^a   Turkmen, Aydin ^a   Sever, Mehmet S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Calcineurin inhibitors; Immunosuppression; Kidney; Nephrotoxicity; Renal; Sirolimus; Transplantation

Indexed keywords

GRAFTS;

CALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; KIDNEY; NEPHROTOXICITY; RENAL; RENAL TRANSPLANT RECIPIENTS; RENAL TRANSPLANTATION; SIDE EFFECT; SIROLIMUS; TRANSPLANTATION;

BODY FLUIDS;

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 77955443206     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2010.01022.x     Document Type: Article

References (50)

1. Calne RY, Rolles K, White DJ, et al. Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979 2 : 1033 1036.
2. Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 1996 16 : 536 547.
3. Curtis JJ, Luke RG, Dubovks E, Diethelm AG, Whelchel JD, Jones P. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 1986 2 : 477 479.
4. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1996 56 : 783 793.
5. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002 346 : 580 590. (Pubitemid 34438820)
6. Nankivell BJ, Borrows RJ, Chir B, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 2333.
7. Mihatsch MJ, Kyo M, Morozumi K, et al. The side effects of cyclosporine-A and tacrolimus. Clin Nephrol 1998 49 : 356 363.
8. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005 56 : 71 85.
9. Cattaneo D, Gotti E, Perico N, Bertolini G, Kainer G, Remuzzi G. Cyclosporine formulation and Kaposi's sarcoma after renal transplantation. Transplantation 2005 80 : 743 748.
10. Flechner SM, Goldfard D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective randomized trial of sirolimus versus cyclosporine. Transplantation 2002 74 : 1070 1076.
11. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002 8 : 128 135.
12. Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000 70 : 1244 1247.
13. Diekmann F, Waiser J, Fritsche L, et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor induced nephrotoxicity. Transplant Proc 2001 33 : 3234 3235.
14. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004 4 : 1869 1875. (Pubitemid 39434449)
15. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005 20 : 2517 2523.
16. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005 16 : 3755 3762.
17. Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009 4 : 860 865.
18. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Tranplantation 2002 74 : 1560 1567.
19. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001 72 : 777 786.
20. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999 67 : 1036 1042.
21. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002 2 : 436 442.
22. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004 15 : 809 817.
23. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005 18 : 22 8.
24. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005 5 : 2496 2503.
25. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States 1988-1996. N Engl J Med 2000 342 : 605 612.
26. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001 16 : 121 124.
27. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001 59 : 3 16.
28. Wyzgal J, Paczek L, Senatorski G, et al. Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 2002 34 : 3185 3187.
29. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006 82 : 1153 1162.
30. Egbuna OI, Davis RB, Chudinski R, et al. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Transplantation 2009 88 : 684 692.
31. Servais A, Meas-Yedid V, Toupance O, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009 9 : 2552 2560.
32. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003 35 : 52 7.
33. Renders L, Steinbach R, Valerius T, et al. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 2004 27 : 181 185.
34. Weber T, Abendroth D, Schelzig H. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. Transpl Int 2005 18 : 151 156.
35. Wu M-S, Chang C-T, Hung C-C. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant 2005 19 : 236 242.
36. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009 87 : 233 242.
37. Sayin B, Karakayali H, Colak T, et al. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion. Transplant Proc 2009 41 : 2789 2793.
38. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006 21 : 562 568.
39. Pinheiro HS, Amaro TA, Braga AM, Bastos MG. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc 2006 38 : 3476 3478.
40. Straathof-Galema L, Wetzels JF, Dijkman HB, et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006 6 : 429 433.
41. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular hemodynamics and proteinuria. Nephrol Dial Transplant 2006 21 : 488 493.
42. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005 80 : 1198 1203.
43. Dittrich E, Schmaldienst S, Soleiman A, et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004 17 : 215 220.
44. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplant Proc 2007 39 : 2151 2152.
45. Sumethkul V, Changsirikulchai S, Lothuvachai T, Chalermsanyakorn P. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy. Transplant Proc 2006 38 : 3470 3472.
46. U.S. Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Ch. 7. Transplantation. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
47. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883 889.
48. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 17 : 581 589.
49. Morales JM, Campistol JM, Kreis H, et al. Sirolimus-Based Therapy With or Without Cyclosporine: Long-Term Follow-up in Renal Transplant Patients. Abstract 775. Washington, DC : American Transplant Congress, 2003.
50. Morales JM, Andres A, Dominguez-Gil B, et al. Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation. Transplant Proc 2003 35 : 154 156.